RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ascletis Pharma Stock

Ascletis Pharma EBIT 2024

Ascletis Pharma EBIT

-313.75 M CNY

Ticker

1672.HK

ISIN

KYG0520K1094

WKN

A2JRKN

In 2024, Ascletis Pharma's EBIT was -313.75 M CNY, a 3.81% increase from the -302.25 M CNY EBIT recorded in the previous year.

The Ascletis Pharma EBIT history

YEAREBIT (undefined CNY)
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-

Ascletis Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ascletis Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ascletis Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ascletis Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ascletis Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ascletis Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ascletis Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ascletis Pharma’s growth potential.

Ascletis Pharma Revenue, EBIT and net profit per share

DateAscletis Pharma RevenueAscletis Pharma EBITAscletis Pharma Net Income
2026e78.99 M undefined-310.73 M undefined-271.18 M undefined
2025e0 undefined-323.85 M undefined-281.23 M undefined
2024e0 undefined-313.75 M undefined-261.14 M undefined
202356.6 M undefined-302.25 M undefined-144.72 M undefined
202254.09 M undefined-399.46 M undefined-314.84 M undefined
202176.9 M undefined-206 M undefined-199 M undefined
202035 M undefined-236.3 M undefined-209.2 M undefined
2019173.4 M undefined-159.6 M undefined-96 M undefined
2018166.3 M undefined-70.3 M undefined-7.3 M undefined
201753.2 M undefined-67.5 M undefined-53.9 M undefined
201633 M undefined-44.3 M undefined-26.8 M undefined

Ascletis Pharma stock margins

The Ascletis Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ascletis Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ascletis Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ascletis Pharma's sales revenue. A higher gross margin percentage indicates that the Ascletis Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ascletis Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ascletis Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ascletis Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ascletis Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ascletis Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ascletis Pharma Margin History

Ascletis Pharma Gross marginAscletis Pharma Profit marginAscletis Pharma EBIT marginAscletis Pharma Profit margin
2026e45.92 %-393.4 %-343.33 %
2025e45.92 %0 %0 %
2024e45.92 %0 %0 %
202345.92 %-534.04 %-255.7 %
2022-45.65 %-738.51 %-582.07 %
202150.98 %-267.88 %-258.78 %
2020-67.14 %-675.14 %-597.71 %
201971.68 %-92.04 %-55.36 %
201892.54 %-42.27 %-4.39 %
2017100 %-126.88 %-101.32 %
2016100 %-134.24 %-81.21 %

Ascletis Pharma Aktienanalyse

What does Ascletis Pharma do?

Ascletis Pharma Inc is a bio-pharmaceutical company that was founded in Hong Kong in 2009. The focus of the company is the development and marketing of drugs for the treatment of infectious diseases and cancer. The business model of Ascletis Pharma Inc is based on research and development, as well as sales and marketing activities. The company collaborates closely with academic institutions and clinical researchers to discover and develop new drugs. In recent years, Ascletis has received various awards and recognitions for its products. The company's portfolio includes various areas, such as the treatment of viral infectious diseases like hepatitis B and C infections. They have also developed drugs for the treatment of solid tumors, such as gastric cancer and liver cancer. Alongside medical research, Ascletis also conducts various sales and marketing activities. The company works with partners to market its products worldwide. In summary, Ascletis Pharma Inc is an emerging bio-pharmaceutical company specializing in the development of drugs for the treatment of infectious diseases and cancer. The business model is based on research and development, as well as sales and marketing of products. The company has various divisions and offers a variety of products. Ascletis has experienced continuous growth in recent years and is considered one of the most innovative companies in the industry. Ascletis Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Ascletis Pharma's EBIT

Ascletis Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ascletis Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ascletis Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ascletis Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ascletis Pharma stock

How much did Ascletis Pharma achieve in EBIT for the current year?

In the current year, Ascletis Pharma has achieved an EBIT of -313.75 M CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Ascletis Pharma.

How has the EBIT of Ascletis Pharma developed in recent years?

The EBIT of Ascletis Pharma has increased by 3.806% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Ascletis Pharma?

The EBIT of Ascletis Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Ascletis Pharma pay?

Over the past 12 months, Ascletis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascletis Pharma is expected to pay a dividend of 0 CNY.

What is the dividend yield of Ascletis Pharma?

The current dividend yield of Ascletis Pharma is .

When does Ascletis Pharma pay dividends?

Ascletis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascletis Pharma?

Ascletis Pharma paid dividends every year for the past 0 years.

What is the dividend of Ascletis Pharma?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascletis Pharma located?

Ascletis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascletis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascletis Pharma from 11/19/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Ascletis Pharma pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Ascletis Pharma in the year 2023?

In the year 2023, Ascletis Pharma distributed 0 CNY as dividends.

In which currency does Ascletis Pharma pay out the dividend?

The dividends of Ascletis Pharma are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ascletis Pharma

Our stock analysis for Ascletis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascletis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.